Another step closer to US Health Care Reform

24 December 2009

US senators are preparing to vote on the final Senate version of a historic health care reform after yesterday's 60-39 vote to end debate on the controversial measure, which is expected to cost $871 billion. This was welcomed by Senate Majority Leader Harry Reid, who said: 'we stand on the doorstep of history.'

However, though defeated, Republicans still took to the floor of the Chamber to lambaste the bill, with Senator Orrin Hatch (Republican, Utah) arguing that it "just might wind up being the most widely hated legislation of the decade."

After 24 consecutive days of debate - the second-longest such stretch ever - the final vote on the Democrats' 10-year, nearly $1 trillion bill is set for early Thursday, Christmas Eve morning, comments The Associated Press. It will be the Senate's first Christmas Eve vote since 1895, when the matter at hand was a military affairs bill concerning employment of former Confederate officers, according to the Senate Historical Office, it said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical